Repotrectinib plus chemotherapy for relapsed solid tumors in youth
Treatments studied
Part of Cancer clinical trials.
This early-phase study tests repotrectinib (a targeted anti-cancer pill) combined with chemotherapy in children and young adults whose solid tumors have come back or did not respond to standard treatment. The goal is to see how safe the treatment is and whether it can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between the allowed ages (≤30 for some parts, and <12 for part of Phase 1, based on study timing).
- Your cancer has relapsed or is refractory, and the study needs measurable/evaluable disease (with specific rules for DIPG).
- You must be well enough to do daily activities: Lansky/Karnofsky performance score must be at least 50.
- Your organs and blood counts must be strong enough (blood counts, kidney, liver, electrolytes, and heart rhythm limits).
- You must have recovered from prior treatments and waited the required time (often 2–6+ weeks, depending on treatment type).
- If you are asked to provide tissue, archived tumor samples must be available (DIPG has different tissue rules).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests repotrectinib, a targeted medicine, in children and young adults whose tumors have specific gene changes involving ROS1 or NTRK. It may help shrink advanced cancers that carry these gene alterations.
This trial studies repotrectinib, a targeted medicine, in people with advanced solid tumors that have specific gene rearrangements (ALK, ROS1, or NTRK). It may help shrink tumors or control cancer growth based on the patient’s tumor genetic result.
This trial tests a new combination of three chemotherapy drugs (irinotecan liposomes, temozolomide, and vincristine) for children and teens with solid tumors that have not responded to or have come back after standard treatment. The goal is to see if this combination can shrink or control the cancer.
This trial tests a new combination of three chemotherapy drugs (eribulin, irinotecan, and temozolomide) for children and young adults whose solid tumors have come back or not responded to standard treatment. The goal is to see if this combination is safe and effective.
This trial tests a combination of four drugs (liposomal irinotecan, vincristine, temozolomide, and anlotinib) for children and teens whose solid tumors have come back or not responded to treatment. The goal is to see if this combination can shrink or control the tumor.
This study tracks the safety and effects of the drug repotrectinib in children aged 4 to under 18 with certain tumors that have a specific genetic change (NTRK fusion). The goal is to see how well the drug works in everyday medical practice in Japan.
Hear when a new Advanced Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.